STOML1 inhibitors represent a chemical class designed to target and inhibit the function of the STOML1 protein, which plays a significant role in cellular processes such as ion channel regulation and membrane dynamics. The precise modulation of STOML1 activity through these inhibitors is crucial for understanding the protein's role in cellular physiology and the underlying mechanisms of its action. The development of STOML1 inhibitors is grounded in the principle of selective inhibition, ensuring that these compounds specifically bind to and inhibit STOML1 without affecting the function of closely related proteins. This specificity is achieved through the identification of unique binding sites on STOML1 that are essential for its activity. By focusing on these sites, researchers can design inhibitors that disrupt the protein's function, thereby elucidating the biological consequences of STOML1 inhibition.
The identification and optimization of STOML1 inhibitors involve a comprehensive approach that includes high-throughput screening, computational modeling, and detailed biochemical and structural analyses. High-throughput screening is the initial step, employing large libraries of chemical compounds to identify those capable of inhibiting STOML1 activity. Compounds that show promise in these screens are then subjected to computational modeling techniques, such as molecular docking and dynamics simulations, to predict how they interact with STOML1 at the molecular level. These predictions guide further chemical modifications to enhance the potency and specificity of the inhibitors. Subsequent experimental validation involves biochemical assays to confirm the inhibitory effect of the compounds on STOML1 activity, alongside structural biology techniques like X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy to reveal the precise interactions between the inhibitors and STOML1. This multi-tiered approach not only identifies effective STOML1 inhibitors but also provides a deep understanding of their mechanism of action, offering valuable insights into the structural and functional aspects of STOML1 within cellular signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Simvastatin could directly reduce STOML1 levels by inhibiting cholesterol synthesis, thus potentially making STOML1's role in cholesterol transfer redundant. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $56.00 | 6 | |
Amiloride • HCl could bind to acid-sensing ion channels, directly competing with STOML1 and potentially leading to its reduced expression or activity. | ||||||
Progesterone | 57-83-0 | sc-296138A sc-296138 sc-296138B | 1 g 5 g 50 g | $20.00 $51.00 $292.00 | 3 | |
Progesterone may suppress STOML1 expression by altering lipid metabolism pathways that STOML1 is involved in, such as cholesterol transfer. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 [Z-Leu- Leu-Leu-CHO] may increase STOML1 degradation by inhibiting the proteasome, affecting its ability to interact with FBXW7 and thus potentially reducing its expression. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil interferes with STOML1 by affecting calcium ion channels, potentially leading to a reduction in STOML1's ion channel modulating activities. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $60.00 $108.00 | 21 | |
Chlorpromazine may disrupt membrane properties, which could counteract STOML1's role in cholesterol transfer and result in decreased STOML1 expression. | ||||||
Cyclosporine | 79217-60-0 | sc-358111 sc-358111A | 100 mg 1 g | $191.00 $992.00 | 2 | |
Cyclosporine could inhibit STOML1 by affecting calcineurin-related signaling pathways that directly regulate STOML1's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin could suppress STOML1 expression by inhibiting the PI3K signaling pathway, which may be involved in STOML1 regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may reduce STOML1 expression by inhibiting mTOR, a pathway that could directly regulate STOML1 levels. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 could inhibit STOML1 by affecting vacuolar-type H+-ATPase, potentially making STOML1's role in cholesterol transfer less critical. | ||||||